Webinars
Live Sessions on FDA Strategy, Regulatory Readiness & Pharma Partnering
Practical sessions for biotech founders, CSOs, and BD leads navigating the critical moments where regulatory decisions determine long term value. Reserve your spot and be the first to receive the date and joining link.
Upcoming · Free Live Webinar
How Biotech Companies Secure Capital: What Investors and Pharma Actually Want to See
Biologics – PXM with Conscious Capital on how U.S. investors assess readiness, the three levers that de risk your company, and how European biotechs attract U.S. capital.
Thursday, August 27
3:00 PM CET / 9:00 AM EDT
Friday, August 28
10:00 AM CET / 4:00 AM EDT
Why Your Regulatory Package Is Killing Your Fundraise — And How to Fix It Before Your Next Round
Investors are asking harder regulatory questions than they were 18 months ago. Most biotech companies don't realize their regulatory gaps are a valuation risk until they're already in the room. This session walks through exactly where packages fall short — and what to fix before your next round.
—For: Series A/B biotech founders, CSOs, CFOs
—Format: 45 min + Q&A
The EU-FDA Gap: What European Biotechs Need to Know Before They File
European biotechs expanding to the US consistently underestimate FDA's requirements. EMA approval does not transfer. This session covers the three gaps that cost companies 12–24 months — and how to close them before they become delays.
—For: European biotech founders, VP Regulatory, CSOs expanding to the US
—Format: 45 min + Q&A
What Pharma BD Teams Find in Due Diligence — And How to Close the Gaps Before They Do
Pharma walks away from deals that should have closed because of regulatory gaps that were fixable. This session walks through an actual pharma BD due diligence checklist — and shows you how to prepare your regulatory package before they find the gaps.
—For: Biotech founders, BD leads, CSOs preparing for out-licensing
—Format: 45 min + Q&A
From Pre-IND to IND: The Regulatory Roadmap That Keeps Your Timeline — and Your Investors — on Track
Delays at the IND stage cascade into fundraising delays, board pressure, and lost partnering momentum. This session covers what FDA needs before and during IND filing — and the decisions that keep your timeline on track.
—For: Biotech founders, CMOs and regulatory leads preparing for IND
—Format: 45 min + Q&A